Gsk (GSK) Non-Current Deffered Revenue (2017 - 2018)
Gsk (GSK) posted Non-Current Deffered Revenue of $24.4 million for Q4 2018, down 16.3% on a QoQ basis from $29.2 million in Q4 2017, and down 16.3% year-over-year from $29.2 million in Q4 2017.
Gsk (GSK) has 2 years of Non-Current Deffered Revenue data on file, last reported at $24.4 million in Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 16.3% year-over-year to $24.4 million; the TTM figure through Dec 2018 stood at $24.4 million (down 16.3% YoY), while the FY2018 annual figure was $25.4 million, down 10.46% from the prior year.
- Non-Current Deffered Revenue fell to $24.4 million in Q4 2018, from $29.2 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $29.2 million in Q4 2017 and bottomed at $24.4 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 24.45 Mn |
| Dec 31, 2017 | 29.21 Mn |